Skip to main content

Table 5 Tumor recurrence and mortality

From: Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial

 

Taurolidine group

(n = 60)

Control group

(n = 60)

P

Adjuvant chemotherapy

14

21

.11

   Colon cancer

11

10

-

   Gastric cancer

1

7

0.02

   Pancreatic cancer

2

4

-

Adjuvant radiotherapy

9

7

0.39

   Colon cancer

7

6

-

   Gastric cancer

2

1

-

   Pancreatic cancer

-

-

-

Follow-up* (months)

50.0 (1.7–72.0)

  

Colon cancer

53.5 (9.0–72.1)

59.2 (19.6–72.0)

0.41

Gastric cancer

39.9 (1.7–72.0)

43.7 (5.7–67.3)

0.84

Pancreatic cancer

15.6 (8.5–34.5)

10.7 (8.8–46.9)

0.66

Overall tumour recurrence rate

19

22

0.35

Type of recurrence

   

Loco-regional recurrence rate

7

12

0.16

Colon cancer

2

4

0.32

Gastric cancer

3

5

0.35

Pancreatic cancer

2

3

0.61

Time to local recurrence* (months)

17.8 (5.6–35.6)

16.0 (5.3–26.5)

0.43

Colon cancer

10.9 and 35.6

18.4 (6.0)

1

Gastric cancer

18.2 (2.9)

14.9 (4.4)

0.39

Pancreatic cancer

5.6 and 21.3

10.8 (7.0)

0.8

Distant metastasis rate

13

18

0.2

Colon cancer

6

8

0.35

Gastric cancer

4

6

0.36

Pancreatic cancer

3

4

0.65

Time to metastasis * (months)

21.0 (5.2–44.5)

14.4 (3.0–35.9)

0.17

Colon cancer

23.7 (11.4–44.5)

19.3 (3.0–35.9)

0.28

Gastric cancer

16.5 (5.2–34.1)

14.0 (5.9–24.1)

0.76

Pancreatic cancer

22.3 (12.3–24.0)

12.3 (4.0–18.6)

0.23

Overall mortality rate

28

25

0.36

Colon cancer

8

7

0.53

Gastric cancer

15

12

0.29

Pancreatic cancer

5

6

-

Time to death * (months)

20.0 (0.1–61.0)

19.6 (0.1–58.5)

0.71

Colon cancer

35.6 (9.0–61.0)

22.1 (0.1–58.5)

0.34

Gastric cancer

12.8 (0.1–58.6)

12.4 (0.8–40.1)

0.65

Pancreatic cancer

15.6 (8.5–34.5)

10.5 (0.8–46.9)

0.66

Causes of death

   

   Cancer-related mortality rate

17

19

0.2

Colon cancer

6

6

-

Gastric cancer

6

8

0.22

Pancreatic cancer

5

5

-

   Perioperative mortality

2

3

0.5

   Others

9

3

 

Tumour progression

15

16

 
  1. Data are mean (SD), median* (range) or number of patients, t-test, chi-squared test (fisher's exact test), for unequal distribution Mann-Whitney U test, and for Kaplan-Meier method Log Rank test were used; perioperative mortality (30 days) TRD group: stomach – myocardial infarction died on postop day 4 (n = 1), stomach – multiorganic failure died on postop day 14 (n = 1); Control group: pancreas – anastomotic leak, multiorganic failure died on day 23 (n = 1), colon – pulmonal embolism died on day 2 (n = 1), stomach – pneumonia died on day 23 (n = 1); follow-up: time to last examination or death